Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple Sclerosis

3 Jan 2025

Abstract excerpt

BACKGROUND AND OBJECTIVES: Levels of activated complement proteins in the CSF are increased in people with multiple sclerosis (MS) and are associated with clinical disease severity. In this study, we determined whether complement activation profiles track with quantitative MRI metrics and liquid biomarkers indicative of disease activity and progression. METHODS: Complement components and activation products...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Complement system in diseases
Share to Multiple Sclerosis Research Studies
Share to Neuroinflammation and Neurodegeneration Mechanisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39752618
DOI: 10.1212/nxi.0000000000200361

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple SclerosisPMID 39752618Read ↗

Complement Activation Is Associated With Disease Severity in Multiple SclerosisSemantic proximity Read ↗

Complement in multiple sclerosis: its role in disease and potential as a biomarker.Semantic proximity Read ↗

Association of Complement Factors With Disability Progression in Primary Progressive Multiple SclerosisSemantic proximity Read ↗

Tissue microarray methodology identifies complement pathway activation and dysregulation in progressive multiple sclerosisSemantic proximity Read ↗

Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody–Associated DiseaseSemantic proximity Read ↗

The association between neurodegeneration and local complement activation in the thalamus to progressive multiple sclerosis outcomeSemantic proximity Read ↗

Plasma proteome in multiple sclerosis disease progressionSemantic proximity Read ↗

Molecular markers in the CSF proteome differentiate neuroinflammatory diseasesSemantic proximity Read ↗

Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect disease activity in multiple sclerosisSemantic proximity Read ↗

CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple SclerosisSemantic proximity Read ↗

C4 genetic structural variations affect multiple sclerosis risk and progressionSemantic proximity Read ↗

Combining CSF and Serum Biomarkers to Differentiate Mechanisms of Disability Worsening in Multiple SclerosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.